[10 years' use of ftorafur in tumor chemotherapy at the Robert Rössle Institute. A retrospective analysis from the clinical-toxologic point of view].
A retrospective analysis from the clinical-toxicological point of view Within a ten-year period a group of 130 patients treated with Ftorafur (FT) was selected randomly and 124 of these patients were evaluated with regard to therapeutic side effects using objective criterions. FT founded to be a therapeutic effective cytostatic drug with only a low level of therapeutic side effects. So FT seems to be combinable with more toxic cytostatics without additional serious toxicity for non-tumor tissues. The peroral FT-application was followed only by low graded side effects in comparison with a higher incidence after intravenous injection or infusion. Most observed FT side effects were: nausea and vomiting, toxic effects on the hematopoetic system and alopecia. No serious neurotoxic effects were observed.
D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D005472:Fluorouracil / Q000031:analogs & derivatives*; D006801:Humans; D008130:Lomustine / Q000008:administration & dosage; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy*; D012189:Retrospective Studies; D013629:Tamoxifen / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D014747:Vinblastine / Q000008:administration & dosage; D014750:Vincristine / Q000008:administration & dosage
D013629:Tamoxifen; D005641:Tegafur; D014750:Vincristine; D014747:Vinblastine; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D005472:Fluorouracil; D008727:Methotrexate
Zehn Jahre Anwendung von Ftorafur in der Tumorchemotherapie am Robert-Rössle-Institut. Eine retrospektive Analyse aus klinisch-toxikologischer Sicht.